Strontium is a divalent cation that is closely chemically related to calcium. Strontium ranelate contains two atoms of stable strontium and an organic moiety (ranelic acid). Strontium increases pre-osteoblast replication, osteoblast differentiation, collagen type 1 synthesis and bone matrix mineralization (Fig. 18.1). In low doses strontium increases the density of the spongy bone. It reduces resorption and stimulates formation of bone, leading to a gain in bone mass and improved bone mechanical properties (Fig. 18.2). In other words, strontium uncouples the activity of the osteoclasts and osteoblasts, in favour of bone formation! Ongoing investigations of its activities have revealed other actions, whose overall effects include improvements in bone geometry, cortical bone thickness, trabecular bone morphology among other effects on bone quality, all of which enhance the strength of the bones. This has been confirmed in human trials with increased bone-specific alkaline phosphatase (a marker of bone formation) and decreased C-terminal peptide (a marker of bone resorption). The increment in bone density is comparable to that achieved by fluoride: up to 20%.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Chapter 18 Strontium Ranelate
Ammann P (2005) Strontium ranelate: a novel mode of action leading to renewed bone quality. Osteoporos Int 16:S11–S15
Fuleihan G (2004) Strontium Ranelate – a novel therapy for osteoporosis or a permutation of the same? N Engl J Med 350:504–506
Marie P (2003) Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate. Osteoporos Int 14(Suppl 3):S9–S12
Marie P (2005) Strontium ranelate: a novel mode of action optimizing bone formation and resorption. Osteoporos Int 16:S7–S10
Meunier P, Roux C, Seeman E et al. (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468
Reginster J, Meunier P (2003) Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int 14(Suppl 3): S56–S65
Seeman E, Devogelaer J, Lorenc R et al. (2008) Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 23:433–438
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bartl, R., Frisch, B. (2009). Strontium Ranelate. In: Osteoporosis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79527-8_18
Download citation
DOI: https://doi.org/10.1007/978-3-540-79527-8_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-79526-1
Online ISBN: 978-3-540-79527-8
eBook Packages: MedicineMedicine (R0)